Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin

Syra Health reported Q3 2026 revenue of $2.56 million, up 52% year over year, and net income of $344,610 versus a $225,902 loss a year earlier. Gross margin rose 1,340 basis points to a record 46.3%, and EBITDA turned positive at $301,725; nine-month operating cash flow was $975,023. Management said the company remains on track for full-year 2026 profitability, while cautioning that contract timing can cause quarterly variability.

Analysis

SYRA’s results improve the case that its operating model can sustain profitability, but the quality and repeatability of earnings matter more than the headline growth rate. The Q3 gross-margin step-up appears tied partly to mix and contract execution; a return toward prior margins would quickly compress earnings at this revenue scale. Nine-month operating cash flow also merits a working-capital check: receivables increased materially, while deferred revenue supported cash conversion. Q3 net income included a tax benefit, and the weighted-average share count rose year over year, so investors should distinguish operating progress from per-share progress and confirm share-count trends in the next filing.

The main near-term catalyst is evidence that recent MCO work converts into recurring, collectible revenue. CMS ACCESS approval is an option on future business, not yet proof of a material revenue stream; recruitment of participating ACOs and contract economics remain unverified. For the next 1–3 months, award timing and Q4 execution will determine whether full-year profitability is achieved. Over 6–18 months, repeatable high-margin population-health contracts could support a more durable earnings base, while staffing contracts may add volume but expose margins to labor costs. The small OTCQB profile raises liquidity and financing-risk sensitivity; reported cash does not remove that risk if receivables collection slows. No valuation, trading liquidity, or contract-level data are supplied, so the earnings release alone does not establish an attractive entry price.

Key Decisions for Investors

• Avoid chasing the release without checking SYRA’s valuation, bid-ask spread, and trading volume; OTC liquidity can overwhelm a fundamentally positive catalyst.
• Put SYRA on an earnings-quality watchlist: verify receivables aging and collections, deferred-revenue conversion, diluted share count, and whether operating cash flow remains positive excluding working-capital tailwinds.
• Treat CMS ACCESS as a catalyst watch, not booked growth. Reassess only after disclosed ACO participation, awarded contracts, and revenue contribution establish commercial traction.
• The thesis weakens if Q4 results miss the 2026 profitability goal, gross margin retreats materially, receivables continue to outgrow revenue, or share issuance accelerates. In the absence of those checks and valuation data, no directional trade is warranted.